New Alliance Capital
65
35M
53
4.06
4
0.18
4
- Stages of investment
- Areas of investment
Summary
New Alliance Capital is the famous VC, which was founded in 2008. The main department of described VC is located in the Shanghai. The venture was found in Asia in China.
We can highlight the next thriving fund investment areas, such as Medical Device, Enterprise. The fund has no exact preference in some founders of portfolio startups. If startup sums 3 or 4 of the founder, the chance for it to be financed is low. For fund there is a match between the country of its foundation and the country of its the most frequent investments - China. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Sight Diagnostics, Wuhan Zebra Express, ShopEx
This New Alliance Capital works on 18 percentage points less the average amount of lead investments comparing to the other organizations. The fund is constantly included in 2-6 deals per year. Deals in the range of 50 - 100 millions dollars are the general things for fund. The high activity for fund was in 2017. Despite it in 2019 the fund had an activity. The increased amount of exits for fund were in 2018. When the investment is from New Alliance Capital the average startup value is 500 millions - 1 billion dollars. Considering the real fund results, this VC is 9 percentage points less often commits exit comparing to other organizations.
The fund was created by Liefeng Qu. We also calculated 3 valuable employees in our database.
The typical case for the fund is to invest in rounds with 5-6 participants. Despite the New Alliance Capital, startups are often financed by Sequoia Capital China, Qiming Venture Partners, OurCrowd. The meaningful sponsors for the fund in investment in the same round are Shenzhen Capital Group, Tranquility Capital, Sequoia Capital China. In the next rounds fund is usually obtained by QJY Capital, Tranquility Capital, Steven Esrick.
Investments analytics
Analytics
- Total investments
- 65
- Lead investments
- 4
- Exits
- 4
- Rounds per year
- 4.06
- Follow on index
- 0.18
- Investments by industry
- Health Care (21)
- Biotechnology (15)
- Manufacturing (11)
- Medical (11)
- Pharmaceutical (9) Show 82 more
- Investments by region
-
- China (56)
- Israel (5)
- United States (2)
- Peak activity year
- 2021
- Number of Unicorns
- 2
- Number of Decacorns
- 2
- Number of Minotaurs
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 10
- Avg. valuation at time of investment
- 80M
- Group Appearance index
- 0.80
- Avg. company exit year
- 14
- Avg. multiplicator
- 920.00
- Strategy success index
- 0.70
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
Company name | Deal date | Industry | Deal stage | Deal size | Location |
---|---|---|---|---|---|
Arnatar Therapeutics | 08 Apr 2024 | Early Stage Venture | 50M | United States, California, San Diego | |
MediTrust Health | 10 Aug 2021 | Internet, Health Care, Medical | Late Stage Venture | 308M | Shanghai, Xuhui, China |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.